Insider Selling: Billiontoone (NASDAQ:BLLN) CEO Sells $313,016.22 in Stock

Billiontoone, Inc. (NASDAQ:BLLN) CEO Oguzhan Atay sold 3,183 shares of the business’s stock in a transaction that occurred on Wednesday, October 14th. The shares were sold at an average price of $98.34, for a total transaction of $313,016.22. Following the transaction, the chief executive officer owned 3,183 shares of the company’s stock, valued at approximately $313,016.22. This represents a 50.00% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Oguzhan Atay also recently made the following trade(s):

• On Thursday, October 15th, Oguzhan Atay sold 5,150 shares of Billiontoone stock. The shares were sold at an average price of $100.23, for a total value of $516,184.50.
• On Wednesday, October 14th, Oguzhan Atay sold 2,667 shares of Billiontoone stock. The shares were sold at an average price of $98.00, for a total value of $261,366.00.
• On Monday, October 12th, Oguzhan Atay sold 2,667 shares of Billiontoone stock. The shares were sold at an average price of $97.61, for a total value of $260,325.87.
• On Monday, October 12th, Oguzhan Atay sold 16,667 shares of Billiontoone stock. The shares were sold at an average price of $93.79, for a total value of $1,563,197.93.
• On Monday, September 28th, Oguzhan Atay sold 2,666 shares of Billiontoone stock. The stock was sold at an average price of $120.64, for a total value of $321,626.24.
• On Monday, September 28th, Oguzhan Atay sold 8,333 shares of Billiontoone stock. The stock was sold at an average price of $120.64, for a total value of $1,005,293.12.
• On Monday, September 14th, Oguzhan Atay sold 5,332 shares of Billiontoone stock. The stock was sold at an average price of $98.00, for a total value of $522,536.00.
• On Monday, September 14th, Oguzhan Atay sold 24,999 shares of Billiontoone stock. The shares were sold at an average price of $100.32, for a total value of $2,507,899.68.
• On Monday, August 3rd, Oguzhan Atay sold 12,500 shares of Billiontoone stock. The shares were sold at an average price of $137.37, for a total value of $1,717,125.00.
• On Monday, August 3rd, Oguzhan Atay sold 32,500 shares of Billiontoone stock. The shares were sold at an average price of $136.95, for a total value of $4,450,875.00.

Billiontoone Price Performance

Billiontoone stock traded down $4.61 during midday trading on Friday, reaching $98.12. The company’s stock had a trading volume of 605,635 shares, compared to its average volume of 654,157. The company has a current ratio of 11.69, a quick ratio of 11.31 and a debt-to-equity ratio of 0.17. The stock has a market cap of $4.63 billion and a PE ratio of 140.17. Billiontoone, Inc. has a 52 week low of $61.96 and a 52 week high of $150.44. The business has a 50-day moving average price of $100.99 and a 200-day moving average price of $101.58.

Billiontoone (NASDAQ:BLLN) last posted its earnings results on Wednesday, August 5th. The company reported $0.15 EPS for the quarter, hitting analysts’ consensus estimates of $0.15. The firm had revenue of $109.45 million during the quarter. Billiontoone had a net margin of 8.04% and a return on equity of 9.96%. On average, sell-side analysts predict that Billiontoone, Inc. will post 0.80 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Integrated Wealth Concepts LLC acquired a new position in shares of Billiontoone in the second quarter valued at approximately $29,000. Family Legacy Financial Solutions LLC bought a new position in Billiontoone in the 3rd quarter valued at approximately $53,000. MCF Advisors LLC boosted its position in Billiontoone by 330.8% during the 2nd quarter. MCF Advisors LLC now owns 448 shares of the company’s stock worth $54,000 after buying an additional 344 shares during the period. Toth Financial Advisory Corp boosted its position in Billiontoone by 60.0% during the 3rd quarter. Toth Financial Advisory Corp now owns 800 shares of the company’s stock worth $85,000 after buying an additional 300 shares during the period. Finally, Caitong International Asset Management Co. Ltd bought a new stake in shares of Billiontoone in the fourth quarter worth $230,000.

Analysts Set New Price Targets

A number of research firms recently issued reports on BLLN. Wall Street Zen cut shares of Billiontoone from a “buy” rating to a “hold” rating in a research report on Saturday, August 8th. Guggenheim raised their target price on shares of Billiontoone from $125.00 to $128.00 and gave the company a “buy” rating in a research report on Thursday, October 1st. Canaccord Genuity Group initiated coverage on shares of Billiontoone in a research note on Wednesday, September 2nd. They set a “buy” rating and a $120.00 target price on the stock. Zacks Research upgraded shares of Billiontoone from a “strong sell” rating to a “hold” rating in a report on Friday, October 2nd. Finally, JPMorgan Chase & Co. lowered their price target on shares of Billiontoone from $145.00 to $130.00 and set an “overweight” rating for the company in a report on Thursday, August 6th. Seven research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $126.25.

About Billiontoone

BillionToOne, Inc (NASDAQ:BLLN) is a molecular diagnostics company that develops blood-based genetic tests designed to provide more information from small amounts of cell-free DNA. The company’s platform uses proprietary molecular counting technology to improve the sensitivity and accuracy of diagnostic testing.

BillionToOne’s primary business is reproductive health testing. Its UNITY portfolio is designed to support prenatal screening, including testing for chromosomal conditions and single-gene disorders, and is intended to provide physicians and expectant parents with information from a maternal blood sample.